International Stem Cell (ISCO) EBT Margin (2010 - 2026)
International Stem Cell's (ISCO) quarterly EBT Margin came in at 2.58% in Q2 2026, down 785.0% year-over-year from 0.38% in Q2 2025, and up 84.03% quarter-over-quarter from 16.15% in Q4 2025.
Powered by 
Analysis
International Stem Cell (ISCO) EBT Margin (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported EBT Margin for 17 consecutive years, with 2.58% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBT Margin fell 785.0% year-over-year to 2.58% in Q2 2026; TTM through Jun 2026 was 2.39%, a 21.0% increase from a year earlier, with the FY2025 full-year figure at 4.59%, down 225.0% from the prior year.
- EBT Margin was 2.58% for Q2 2026 at International Stem Cell, up from 16.15% in the prior quarter.
- Over five years, EBT Margin peaked at 5.27% in Q2 2025 and troughed at 24.25% in Q4 2023.
- A 5-year average of 5.58% and a median of 2.58% in 2026 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin jumped 3568 bps in 2022 and slumped 2540 bps in 2023, its largest moves.
- Over 5 years, EBT Margin stood at 1.15% in 2022, then sank by 2204 bps to 24.25% in 2023, then surged by 102 bps to 0.49% in 2024, then plunged by 3392 bps to 16.15% in 2025, then surged by 84 bps to 2.58% in 2026.
- The last three EBT Margin figures came in at 2.58% (Q2 2026), 16.15% (Q4 2025), and 2.41% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -24,299.18% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 2.88% |
| 10 | International Stem Cell | 2.84 Mn | 1.75 Mn | 1.46 Mn | -2.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.58% |
| Dec 31, 2025 | -16.15% |
| Sep 30, 2025 | 2.41% |
| Jun 30, 2025 | 5.27% |
| Mar 31, 2025 | -12.02% |
| Dec 31, 2024 | 0.49% |
| Sep 30, 2024 | -5.74% |
| Jun 30, 2024 | 4.89% |
| Mar 31, 2024 | -10.05% |
| Dec 31, 2023 | -24.25% |
| Sep 30, 2023 | -6.64% |
| Jun 30, 2023 | -9.72% |
| Mar 31, 2023 | -1.63% |
| Dec 31, 2022 | 1.15% |
| Sep 30, 2022 | -19.67% |
| Jun 30, 2022 | -0.10% |
| Mar 31, 2022 | -0.45% |
| Dec 31, 2021 | -19.75% |
| Sep 30, 2021 | -34.80% |
| Jun 30, 2021 | -24.28% |